Moderna Inc.
Moderna Reports Q1 2024 Financial Results and Business Updates
Summary
Moderna, Inc. reported its financial results for the first quarter of 2024, revealing total revenues of $167 million, a GAAP net loss of $1.2 billion, and GAAP diluted EPS of $(3.07). The company's revenue decline was primarily due to reduced sales of its COVID-19 vaccine. Moderna also announced the initiation of three new clinical studies for its individualized neoantigen therapy in combination with Merck's Keytruda for various cancers. Additionally, the company advanced three new vaccine programs towards Phase 3 clinical trials. Moderna reaffirmed its 2024 expected product sales of approximately $4 billion and anticipates numerous product milestones across its vaccines and therapeutics portfolio.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement